E For L Aim PCL (BKK:EFORL-R) Debt-to-Revenue : 0.27 (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BKK:EFORL-R E For L Aim PCL BKK:EFORL-R
40 GF Score
Price ฿0.12
GF Value ฿0.14
Valuation Modestly Undervalued
! 7 Warning Signs
View Full Analysis

What is E For L Aim PCL Debt-to-Revenue?

E For L Aim PCL BKK:EFORL-R 40 Debt-to-Revenue is 0.27 as of Jun. 2026. GuruFocus rates BKK:EFORL-R with a GF Score™ of 40/100 and a GF Value™ of ฿0.14 (Modestly Undervalued). The stock has 7 warning signs investors should review.

Debt-to-Revenue measures a company's ability to pay off its debt.

E For L Aim PCL's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2026 was ฿164 Mil. E For L Aim PCL's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2026 was ฿108 Mil. E For L Aim PCL's annualized Revenue for the quarter that ended in Jun. 2026 was ฿1,009 Mil. E For L Aim PCL's annualized Debt-to-Revenue for the quarter that ended in Jun. 2026 was 0.27.

E For L Aim PCL Debt-to-Revenue Historical Data

* Premium members only.

The historical data trend for E For L Aim PCL's Debt-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

E For L Aim PCL Debt-to-Revenue Chart

E For L Aim PCL Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Debt-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.36 0.39 0.36 0.28 0.23

E For L Aim PCL Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Debt-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.22 0.22 0.23 0.27 0.27

BKK:EFORL-R vs MCK, COR, CAH: Debt-to-Revenue Comparison

For the Medical Distribution subindustry, E For L Aim PCL's Debt-to-Revenue, along with its competitors' market caps and Debt-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

E For L Aim PCL Debt-to-Revenue vs Medical Distribution Industry

For the Medical Distribution industry and Healthcare sector, E For L Aim PCL's Debt-to-Revenue distribution charts can be found below:

* The bar in red indicates where E For L Aim PCL's Debt-to-Revenue falls into.


BKK:EFORL-R
40GF Score
E For L Aim PCL BKK:EFORL-R
Debt-to-Revenue is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

E For L Aim PCL Debt-to-Revenue Calculation

Debt-to-Revenue measures a company's ability to pay off its debt.

E For L Aim PCL's Debt-to-Revenue for the fiscal year that ended in Dec. 2025 is calculated as

Debt-to-Revenue=Total Debt / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(162.23 + 138.496) / 1305.568
=0.23

E For L Aim PCL's annualized Debt-to-Revenue for the quarter that ended in Jun. 2026 is calculated as

Debt-to-Revenue=Total Debt / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(164.372 + 107.627) / 1008.78
=0.27

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-Revenue, the Revenue of the last fiscal year is used. In calculating the annualized quarterly data, the Revenue data used here is four times the quarterly (Jun. 2026) Revenue data.

Frequently Asked Questions Learn more about Debt-to-Revenue →
What does a Debt-to-Revenue of 0.27 mean?
E For L Aim PCL (BKK:EFORL-R) has a Debt-to-Revenue of 0.27 as of Jun. 2026.
Is E For L Aim PCL's Debt-to-Revenue too high?
E For L Aim PCL's current Debt-to-Revenue is 0.27. Overall, E For L Aim PCL has a GF Score™ of 40/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does E For L Aim PCL's Debt-to-Revenue compare to MCK and COR?
E For L Aim PCL's Debt-to-Revenue of 0.27 can be compared against companies in the Medical Distribution industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Revenue for a Medical Distribution company?
A good Debt-to-Revenue depends on the Medical Distribution industry context. However, Debt-to-Revenue should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Revenue mean?
A high Debt-to-Revenue can signal that a stock is expensive relative to its fundamentals. E For L Aim PCL's current Debt-to-Revenue is 0.27. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is E For L Aim PCL stock overvalued right now?
Based on GuruFocus' analysis, E For L Aim PCL (BKK:EFORL-R) is currently considered Modestly Undervalued. The stock's GF Value™ is ฿0.14, compared to a current price of ฿0.12 — trading 14.3% below its estimated fair value. The current Debt-to-Revenue is 0.27. E For L Aim PCL's overall GF Score™ is 40/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Revenue calculated?
Debt-to-Revenue is calculated from a company's financial statements. For E For L Aim PCL (BKK:EFORL-R), the current Debt-to-Revenue is 0.27 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is E For L Aim PCL (BKK:EFORL-R) Overvalued in 2026?

Based on GuruFocus' analysis, E For L Aim PCL stock appears to be undervalued. The current stock price of ฿0.12 is trading 14.3% below its estimated GF Value™ of ฿0.14. GuruFocus considers E For L Aim PCL to be Modestly Undervalued.

Key valuation signals for BKK:EFORL-R:

  • Debt-to-Revenue: 0.27
  • GF Value™: ฿0.14 vs. price of ฿0.12 (14.3% below fair value)
  • GF Score™: 40/100 with 7 warning signs

No single metric tells the full story. See the BKK:EFORL-R stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

E For L Aim PCL Business Description

Other Exchanges EFORL:Thailand
Address 432, Rajavithi road, Bangyeekhan Sub District, Bangplad District, Bangkok, THA, 10700
E For L Aim PCL is engaged in the distribution of medical devices and equipment. The company and subsidiary have distributor agreements for medical devices and equipment with foreign companies. Its products include Patient Monitor System, Central Monitors System, Defibrillator, Automated External Defibrillator (AED), Electrocardiographs, Electroencephalogram (EEG), PSG System (Sleep Labs), and Accessories and Consumables. The group is principally engaged in one operating segment which is the distribution of medical device and equipment and providing service of medical equipment. Their operations are carried out in Thailand.
40GF Score

Get the complete analysis for BKK:EFORL-R

Debt-to-Revenue is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

฿0.12
Price
฿0.14
GF Value